According to the new market research “Cellular Health Testing Market by Type (Single (Telomere, Oxidative Stress, Inflammation, Heavy Metal), Multitest), Sample (Blood, Saliva, Serum, Urine), Collection Site (Home, Office, Hospital, Diagnostic Labs), and Region - Global Forecast to 2022", analyzes and studies the major market drivers, restraints/challenges, and opportunities. The global cellular health screening market is estimated to reach USD 3.42 billion by 2022 from USD 2.12 billion in 2017, at a CAGR of 10.0% during the forecast period.
The global Cellular Health Testing market is segmented based on type, sample, collection site and region.
Based on type, the global cellular health screening market is segmented into single test panels and multi-test panels. In 2017, the single test panels segment is expected to account for the largest share of the global cellular health screening market. These panels are used to get accurate information about a single biomarker and understand how it affects the health of an individual. The preference for multi-test panels is increasing in the market as they provide results for multiple biomarkers in a single exam.
Download a PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=227041930
Browse and in-depth TOC on in “Cellular Health Testing Market "
71 - Tables
32 - Figures
140 - Pages
By sample collection site, the global cellular health screening market is segmented into at-home, in-office, and other sample collection sites. The at-home segment is expected to register the highest CAGR during the forecast period. The availability of diagnostic and therapeutic products that can be used by patients at home without assistance from healthcare professionals are expected to boost the demand for cellular health screening in this segment.
Request Free Sample Report @
In 2017, North America is expected to dominate the global market. Factors such as growing government focus towards preventive healthcare, increasing burden of chronic diseases, increasing research activities, rising geriatric population, and growing number of local players operating in the region are expected to drive the growth of this regional segment.
The key players in the Cellular Health Testing market are Bio-Rad Laboratories (U.S.), GE Healthcare (U.S.), Thermo Fisher Scientific Inc. (U.S.), Danaher Corporation (U.S.), Agilent Technologies (U.S.), Merck Millipore (U.S.), PerkinElmer, Inc. (U.S.), QIAGEN N.V. (Netherlands), Lonza Group Ltd. (Switzerland), Shimadzu Corporation (Japan), Harvard Bioscience, Inc. (U.S.), Sebia Group (U.K.), and C.B.S. Scientific Company, Inc. (U.S.).
View Complete Press Release @